AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8174531 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone/Ketamine
Number of subjects: 75
Study 8174531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 75
Study 3064776 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy irradiation + CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 0
Study 3064776 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy irradiation + TAM (tamoxifen)
Number of subjects: 0
Study 3064776 — intervention group
Group type: COMPARATOR
Intervention: CMF alone
Number of subjects: 0
Study 3064776 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF + TAM
Number of subjects: 0
Study 3064776 — intervention group
Group type: COMPARATOR
Intervention: TAM alone
Number of subjects: 0
Study 3064776 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated patients (both pre- and postmenopausal)
Number of subjects: 0
Study 3064776 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic treatment alone (chemotherapy and/or tamoxifen)
Number of subjects: 0
Study 31895881 — intervention group
Group type: EXPERIMENTAL
Intervention: wSp 0.1 mg
Number of subjects: 42
Study 31895881 — intervention group
Group type: EXPERIMENTAL
Intervention: wSp 0.3 mg
Number of subjects: 42
Study 31895881 — intervention group
Group type: EXPERIMENTAL
Intervention: wSp 0.6 mg
Number of subjects: 42
Study 31895881 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 42
Study 30243202 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a minimally invasive catheter for ETT positioning
Number of subjects: 69
Study 30243202 — intervention group
Group type: COMPARATOR
Intervention: Without the catheter
Number of subjects: 69
Study 26797698 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row (DR) repair
Number of subjects: 58
Study 26797698 — intervention group
Group type: COMPARATOR
Intervention: Single-row (SR) repair
Number of subjects: 58
Study 24314016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prophylaxis with tongue cleaning
Number of subjects: 30
Study 24314016 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 22411724 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated cannabis extract
Number of subjects: 9
Study 22411724 — intervention group
Group type: EXPERIMENTAL
Intervention: Unheated cannabis extract
Number of subjects: 9
Study 22411724 — intervention group
Group type: COMPARATOR
Intervention: Synthetic THC (dronabinol)
Number of subjects: 9
Study 20425166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of simvastatin and ezetimibe
Number of subjects: 1873
Study 20425166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study 18077786 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 60
Study 18077786 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 60
Study 16897905 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapist playing and singing continually to the child
Number of subjects: 17
Study 16897905 — intervention group
Group type: COMPARATOR
Intervention: Switch-activated pig toy
Number of subjects: 17
Study 16897905 — intervention group
Group type: COMPARATOR
Intervention: Switch-activated recorded music
Number of subjects: 17
Study 16897905 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapist playing and singing contingent upon child touching the guitar
Number of subjects: 17
Study 12923133 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 at doses of 1-100 mg
Number of subjects: 36
Study 12923133 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 at 200 mg
Number of subjects: 36
Study 12923133 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 at doses of 10, 50, 100 and 200 mg
Number of subjects: 36
Study 12923133 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914
Number of subjects: 36
Study 12212206 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg.d-1
Number of subjects: 47
Study 12212206 — intervention group
Group type: COMPARATOR
Intervention: Control (no simvastatin)
Number of subjects: 47
Study 12212206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 8831319 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous cranial electrical stimulation (TCES)
Number of subjects: 39
Study 8831319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TCES)
Number of subjects: 39
Study 8831319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TCES and Control)
Number of subjects: 39
Study 8488308 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized AIDS education program (S)
Number of subjects: 858
Study 8488308 — intervention group
Group type: COMPARATOR
Intervention: Traditional AIDS education program (T)
Number of subjects: 858
Study 8488308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both programs (S and T)
Number of subjects: 858
Study 3545116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 18
Study 3545116 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 18
Study 3545116 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin vs Metoprolol
Number of subjects: 18
Study 30193571 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming (AW) with a forced-air warming system
Number of subjects: 62
Study 30193571 — intervention group
Group type: COMPARATOR
Intervention: Passive warming (PW) with application of a cotton blanket
Number of subjects: 62
Study 27177805 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT + CM
Number of subjects: 214
Study 27177805 — intervention group
Group type: COMPARATOR
Intervention: HAT-only
Number of subjects: 214
Study 23163982 — intervention group
Group type: EXPERIMENTAL
Intervention: NCLF‐US thrice per week (Group 1)
Number of subjects: 12
Study 23163982 — intervention group
Group type: EXPERIMENTAL
Intervention: NCLF‐US once per week (Group 2)
Number of subjects: 12
Study 23163982 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 12
Study 23650900 — intervention group
Group type: EXPERIMENTAL
Intervention: NAV (Freestyle® Navigator I)
Number of subjects: 20
Study 23650900 — intervention group
Group type: EXPERIMENTAL
Intervention: ENL (Paradigm® with Enlite™ sensor)
Number of subjects: 20
Study 23650900 — intervention group
Group type: COMPARATOR
Intervention: G4A (Dexcom® G4™ version A sensor)
Number of subjects: 20
Study 20876317 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy followed by postoperative chemotherapy
Number of subjects: 104
Study 20876317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear p-STAT3 expression
Number of subjects: 104
Study 18361816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion releasing under brachial plexus block
Number of subjects: 60
Study 18361816 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion releasing under stellate ganglion block
Number of subjects: 60
Study 18361816 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited adhesion releasing under stellate ganglion block
Number of subjects: 60
Study 18361816 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrolysis under stellate ganglion block
Number of subjects: 60
Study 18361816 — intervention group
Group type: COMPARATOR
Intervention: Block + manipulation treatment (Group I)
Number of subjects: 60
Study 16178642 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-OCT-V
Number of subjects: 16
Study 16178642 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-OCT-M
Number of subjects: 16
Study 12663299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber rye foods
Number of subjects: 28
Study 12663299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber wheat foods
Number of subjects: 28
Study 12663299 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber refined-cereal foods
Number of subjects: 28
Study 10994616 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. for 2 weeks
Number of subjects: 29
Study 10994616 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 29
Study 8772566 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic GHRH administration (200 micrograms, 4 boluses of 50 micrograms each at 2200, 2300, 2400, and 0100 h)
Number of subjects: 0
Study 8772566 — intervention group
Group type: COMPARATOR
Intervention: Continuous GHRH infusion (57 micrograms/h between 2130 and 0100 h)
Number of subjects: 0
Study 8772566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1290611 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled resin
Number of subjects: 161
Study 1290611 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid resins
Number of subjects: 161
Study 1290611 — intervention group
Group type: COMPARATOR
Intervention: All resins (microfilled and hybrid)
Number of subjects: 161
Study 3158254 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms/kg atracurium
Number of subjects: 15
Study 3158254 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/kg atracurium
Number of subjects: 15
Study 3158254 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms/kg atracurium
Number of subjects: 15
Study 3158254 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium steady-state infusion during halothane or isoflurane anesthesia
Number of subjects: 15
Study 3158254 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium steady-state infusion during balanced anesthesia
Number of subjects: 15
Study 30168810 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina Self-Management (ASM) intervention (n = 39)
Number of subjects: 80
Study 30168810 — intervention group
Group type: COMPARATOR
Intervention: Attention-control telephone call (n = 41)
Number of subjects: 80
Study 26673811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg daily)
Number of subjects: 280
Study 26673811 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus (175 mg on days 1, 8, and 15 of cycle 1; 75 mg on days 1, 8, and 15 of subsequent cycles)
Number of subjects: 280
Study 26673811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 280
Study 26673811 — intervention group
Group type: COMPARATOR
Intervention: Temsirolimus
Number of subjects: 280
Study 23812324 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 1069
Study 23812324 — intervention group
Group type: COMPARATOR
Intervention: Latest generation HDTV colonoscopy
Number of subjects: 1069
Study 23812324 — intervention group
Group type: COMPARATOR
Intervention: Image-based recommendations for post-polypectomy surveillance
Number of subjects: 1069
Study 23812324 — intervention group
Group type: COMPARATOR
Intervention: Post hoc analysis of polyp photographs
Number of subjects: 1069
Study 22419603 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 42
Study 22419603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20111953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular polynucleotides (n = 30)
Number of subjects: 60
Study 20111953 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronan (n = 30)
Number of subjects: 60
Study 18522727 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of cognac (1.2 +/- 0.1 dl)
Number of subjects: 23
Study 18522727 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of cognac (2.4 +/- 0.3 dl)
Number of subjects: 23
Study 18522727 — intervention group
Group type: COMPARATOR
Intervention: Control day
Number of subjects: 23
Study 16265683 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III RCT with adequate sample size
Number of subjects: 228
Study 16265683 — intervention group
Group type: COMPARATOR
Intervention: Negative RCT with inadequate sample size
Number of subjects: 228
Study 16265683 — intervention group
Group type: COMPARATOR
Intervention: Negative RCT
Number of subjects: 228
Study 16265683 — intervention group
Group type: COMPARATOR
Intervention: Phase III trials without power calculations
Number of subjects: 228
Study 12438009 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 18
Study 12438009 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women
Number of subjects: 18
Study 10050702 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin (4500 anti-Xa IU)
Number of subjects: 440
Study 10050702 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin (40 mg, 4000 anti-Xa IU)
Number of subjects: 440
Study 10050702 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin
Number of subjects: 440
Study 10050702 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin and enoxaparin
Number of subjects: 440
Study 7486040 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamylal (4.0‐5.0 mg/kg)
Number of subjects: 90
Study 7486040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1.5‐2.0 mg/kg)
Number of subjects: 90
Study 7486040 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1.0 mg/kg) - Control Group O
Number of subjects: 90
Study 7486040 — intervention group
Group type: COMPARATOR
Intervention: Control Group O
Number of subjects: 90
Study 2077498 — intervention group
Group type: COMPARATOR
Intervention: Combination of chloral hydrate and hydroxyzine (placebo control)
Number of subjects: 22
Study 2077498 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate (three doses)
Number of subjects: 22
Study 2077498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6778329 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-adrenergic combination (diphenhydramine and pseudoephedrine)
Number of subjects: 55
Study 6778329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31763948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejaculatory hood sparing vaporization
Number of subjects: 49
Study 31763948 — intervention group
Group type: COMPARATOR
Intervention: Standard prostate vaporization
Number of subjects: 49
Study 30345635 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI with automated coregistration
Number of subjects: 200
Study 30345635 — intervention group
Group type: COMPARATOR
Intervention: OCT-guided PCI without automated coregistration
Number of subjects: 200
Study 28117242 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 92
Study 28117242 — intervention group
Group type: COMPARATOR
Intervention: Angiography alone (CA)
Number of subjects: 92
Study 25541338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid 1.5 g in povidone-iodine solution (group B)
Number of subjects: 125
Study 25541338 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid 3.0 g in povidone-iodine solution (group C)
Number of subjects: 125
Study 25541338 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine solution (control: group A)
Number of subjects: 125
Study 23773380 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (cALND)
Number of subjects: 474
Study 23773380 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation (RNI)
Number of subjects: 474
Study 21389184 — intervention group
Group type: EXPERIMENTAL
Intervention: Cola
Number of subjects: 16
Study 21389184 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Cola
Number of subjects: 16
Study 21389184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Water
Number of subjects: 16
Study 19203565 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CLR) 500 mg oral dose (Group 1: Merck; Group 2: Klaricid)
Number of subjects: 0
Study 17381500 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir (twice daily)
Number of subjects: 320
Study 17381500 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (once daily)
Number of subjects: 320
Study 14988471 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 0
Study 14988471 — intervention group
Group type: COMPARATOR
Intervention: Dairy products
Number of subjects: 0
Study 11481926 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.243% sodium fluoride and dicalcium phosphate dihydrate)
Number of subjects: 2506
Study 11481926 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 2506
Study 11481926 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice
Number of subjects: 2506
Study 11481926 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice
Number of subjects: 2506
Study 9722821 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced (outreach-assisted) intervention
Number of subjects: 60
Study 9722821 — intervention group
Group type: COMPARATOR
Intervention: Minimal (self-tell) intervention
Number of subjects: 60
Study 8068588 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of metronidazole three times daily for 5 days
Number of subjects: 62
Study 8068588 — intervention group
Group type: COMPARATOR
Intervention: 400 mg of metronidazole twice daily for 5 days
Number of subjects: 62
Study 2743379 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 2,500 ppm F
Number of subjects: 16
Study 2743379 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste containing 1,500 ppm F
Number of subjects: 16
Study 1273228 — intervention group
Group type: EXPERIMENTAL
Intervention: Backup reinforcement condition (feedback plus choice of money or extra experimental credit)
Number of subjects: 80
Study 1273228 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional feedback condition
Number of subjects: 80
Study 1273228 — intervention group
Group type: COMPARATOR
Intervention: Yoked control condition (received bogus feedback)
Number of subjects: 80
Study 1273228 — intervention group
Group type: COMPARATOR
Intervention: Control condition (received no feedback)
Number of subjects: 80
Study 31126306 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine and electrolyte formulated multi‐ingredient performance supplement (MIPS)
Number of subjects: 22
Study 31126306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29035384 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment
Number of subjects: 0
Study 26454528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tube placement with adenoidectomy (Group II)
Number of subjects: 137
Study 26454528 — intervention group
Group type: COMPARATOR
Intervention: Tympanostomy tube placement without adenoidectomy (Group I)
Number of subjects: 137
Study 24495636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure therapy (PT)
Number of subjects: 20
Study 21467539 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat conditions
Number of subjects: 0
Study 21467539 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender stereotypes
Number of subjects: 0
Study 21467539 — intervention group
Group type: EXPERIMENTAL
Intervention: High legitimation of sociopolitical system
Number of subjects: 0
Study 18632424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg per day for nine days, starting 48 hours before CPB, with an additional dose of 40 mg one hour after surgery
Number of subjects: 43
Study 18632424 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pravastatin)
Number of subjects: 43
Study 16701183 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial plus musculocutaneous nerve stimulation
Number of subjects: 60
Study 16701183 — intervention group
Group type: COMPARATOR
Intervention: Ulnar plus musculocutaneous nerve stimulation
Number of subjects: 60
Study 12944447 — intervention group
Group type: EXPERIMENTAL
Intervention: gum elastic bougie
Number of subjects: 60
Study 12944447 — intervention group
Group type: COMPARATOR
Intervention: stylet
Number of subjects: 60
Study 10840172 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 17
Study 10840172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9375951 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 0
Study 8238159 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 3 gm intravenously every 6 hours for 72 hours
Number of subjects: 75
Study 8238159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: N 10 mg six times daily
Number of subjects: 29
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: V 80 mg three times daily
Number of subjects: 29
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN 10 mg six times daily
Number of subjects: 29
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: N 20 mg six times daily
Number of subjects: 29
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: V 120 mg four times daily
Number of subjects: 29
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN 20 mg six times daily
Number of subjects: 29
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: N r 20 mg four times daily
Number of subjects: 29
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: V r 120 mg three times daily
Number of subjects: 29
Study 3514224 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN sr 40 mg four times daily
Number of subjects: 29
Study 30883414 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia exposure
Number of subjects: 131
Study 30883414 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational cohort studies
Number of subjects: 131
Study 30414448 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, personalized worksite intervention combining environmental strategy (traffic‐light labeling) with objective feedback and personalized nudges (health/lifestyle tips, social norms, incentives)
Number of subjects: 602
Study 30414448 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, personalized worksite intervention
Number of subjects: 602
Study 26230902 — intervention group
Group type: EXPERIMENTAL
Intervention: PDX/GOS (formula with 4 g/L of PDX/GOS)
Number of subjects: 157
Study 26230902 — intervention group
Group type: COMPARATOR
Intervention: Control (cow's milk-based formula)
Number of subjects: 157